SAN DIEGO Karim Kader, M.D., Ph.D., associate clinical professor at the UC San Diego School of Medicine, together with a team of researchers from Wake Forest University School of Medicine, have developed a genetic test to predict a man's risk for prostate cancer. Use of the test could reduce the need for repeat biopsies in men who have had a negative biopsy. Results of the multicenter study were recently published online in the journal of European Urology. "The genetic test outperformed the PSA test in assessing cancer risk," said Kader, co-investigator and urologic surgeon at UC San Diego Health System. "If results of this blood test were factored into prostate cancer predictors such as total free PSA, free PSA, number of core samples taken at biopsy and family history, we would have a more accurate picture of a whether or not a man is likely to develop the sometimes fatal disease." Kader and researchers evaluated 1,654 men in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) clinical trial. All the men had biopsies and consented to genetic studies that looked for the presence of germline single nucleotide polymorphisms (SNPs). SNPs are genetic variations within an individual's DNA sequence which … Continue reading →

ScienceDaily (July 17, 2012) Karim Kader, MD, PhD, associate clinical professor at the UC San Diego School of Medicine, together with a team of researchers from Wake Forest University School of Medicine, have developed a genetic test to predict a man's risk for prostate cancer. Use of the test could reduce the need for repeat biopsies in men who have had a negative biopsy. Results of the multicenter study were recently published online in the journal of European Urology. "The genetic test outperformed the PSA test in assessing cancer risk," said Kader, co-investigator and urologic surgeon at UC San Diego Health System. "If results of this blood test were factored into prostate cancer predictors such as total free PSA, free PSA, number of core samples taken at biopsy, and family history, we would have a more accurate picture of a whether or not a man is likely to develop the sometimes fatal disease." Kader and researchers evaluated 1,654 men in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) clinical trial. All the men had biopsies and consented to genetic studies that looked for the presence of germline single nucleotide polymorphisms (SNPs). SNPs are genetic variations within an individual's DNA … Continue reading →

Public release date: 17-Jul-2012 [ | E-mail | Share ] Contact: Jacque Montgomery jacque.montgomery@ucdenver.edu 303-928-9093 University of Colorado Denver AURORA, Colo. (July 17, 2012) Researchers at the University of Colorado School of Medicine have found a drug that boosts memory function in those with Down syndrome, a major milestone in the treatment of this genetic disorder that could significantly improve quality of life. "Before now there had never been any positive results in attempts to improve cognitive abilities in persons with Down syndrome through medication," said Alberto Costa, MD, Ph.D., who led the four- year study at the CU School of Medicine. "This is the first time we have been able to move the needle at all and that means improvement is possible." The study was published today in the journal Translational Psychiatry. Costa, an associate professor of medicine, and his colleagues studied 38 adolescents and young adults with Down syndrome. Half took the drug memantine, used to treat Alzheimer's disease, and the others took a placebo. Costa's research team hypothesized that memantine, which improved memory in mice with Down syndrome, could increase test scores of young adults with the disorder in the area of spatial and episodic memory, functions … Continue reading →

LEUVEN, BELGIUM--(Marketwire -07/17/12)- TiGenix (EURONEXT:TIG), the European leader in cell therapy, announced today that after obtaining national reimbursement for ChondroCelect in the Netherlands last month, the company has now contracted with four major hospitals to make its innovative cartilage repair therapy available to their patients on a routine basis: University Medical Center Utrecht, University Hospital Maastricht, Martini Hospital Groningen, and, most recently, the Elisabeth Hospital Tilburg. Discussions with other Cartilage Expert Centers are ongoing. Reimbursement for ChondroCelect in the Netherlands is retroactive per January 1, 2011. "Our close collaboration with the Dutch hospitals is key to making ChondroCelect available to patients in the Netherlands," said Eduardo Bravo, CEO of TiGenix. "Dutch scientists and clinicians have made important contributions to the development of this innovative cartilage repair therapy. Patients who suffer from cartilage lesions in the knee that cause recurrent pain and can be incapacitating can now be routinely treated and literally find their footing again. We expect to soon expand the number of hospitals in the Netherlands where ChondroCelect is available." Damage to the articular cartilage in the knee can be caused by sports or professional activities in which the knee is repeatedly and forcefully impacted. It is a condition … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/tntbmr/antibodymediated) has announced the addition of John Wiley and Sons Ltd's new report "Antibody-Mediated Drug Delivery Systems: Concepts, Technology, and Applications" to their offering. A comprehensive guide to the concepts, technology, and applications of antibody-mediated drug delivery systems Antibody-Mediated Drug Delivery Systems: Concepts, Technology, and Applications provides readers with comprehensive coverage of one of the fastest growing fields of pharmaceutical and biotechnology research. An up-to-date, practical reference on the essential ideas, analytical developments, processing, and utilization of antibody-mediated drug delivery systems, this edited volume features contributions from acclaimed experts from around the globe. Each of the twenty-two chapters explores the opportunities, challenges, and uses of antibody-mediated delivery systems for generating novel therapeutic treatments. Topics covered include targeted treatments for cancer, cardiovascular diseases, asthma, and other conditions, as well as brain drug delivery, vaccine delivery, plant-derived antibodies, gene therapy, and more. Six of the ten bestselling drugs on the market today are therapeutic antibodies, yet no definitive and detailed review of current developments in the field has been published since 1988. Antibody-Mediated Drug Delivery Systems fills this hole in the literature, with insightful coverage of the full spectrum of essential concepts, technologies, and applications of these … Continue reading →